Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753777 · ClinicalTrials.gov registry record
Autoimmune Blistering Diseases Study
A clinical trial of Pemphigus Vulgaris and Bullous Pemphigoid, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT02753777 is a study of Pemphigus Vulgaris and Bullous Pemphigoid that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 150 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT02753777, a study of Pemphigus Vulgaris and Bullous Pemphigoid, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Conditions Studied
Interventions
- OTHER Questionnaires
Study Locations (3)
Pennsylvania
- Hospital of the University of Pennsylvania, Department of Dermatology - Philadelphia
- Hospital of the University of Pennsylvania - Philadelphia
- University of Pennsylvania, Department of Dermatology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-04 |
| Est. Completion | 2030-01-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02753777
The ClinicalTrials.gov registry entry for NCT02753777 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pemphigus Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT02753777 reports 3 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02753777 about?
NCT02753777 is a clinical study titled "Autoimmune Blistering Diseases Study". Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
What is the current status of trial NCT02753777?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2016-04. Estimated completion is 2030-01-02.
What conditions does trial NCT02753777 study?
This clinical trial studies the following conditions: Pemphigus Vulgaris, Bullous Pemphigoid, Pemphigus Foliaceus.
What interventions are being tested in trial NCT02753777?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT02753777?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02753777 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pemphigus Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
RECRUITING · Phase 1
-
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.